Heloísa Resende

ORCID: 0000-0003-4692-3743
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Women's cancer prevention and management
  • Breast Cancer Treatment Studies
  • Global Cancer Incidence and Screening
  • Public Health in Brazil
  • Cancer Risks and Factors
  • Economic and Financial Impacts of Cancer
  • Cancer survivorship and care
  • Advanced Breast Cancer Therapies
  • Health Systems, Economic Evaluations, Quality of Life
  • BRCA gene mutations in cancer
  • Colorectal and Anal Carcinomas
  • Ethics in Clinical Research
  • Breast Lesions and Carcinomas
  • Biosimilars and Bioanalytical Methods
  • Cancer Genomics and Diagnostics
  • Chronic Lymphocytic Leukemia Research
  • Colorectal Cancer Surgical Treatments
  • Palliative and Oncologic Care
  • Healthcare during COVID-19 Pandemic
  • Autoimmune and Inflammatory Disorders Research
  • Rheumatoid Arthritis Research and Therapies
  • Medication Adherence and Compliance
  • Tuberculosis Research and Epidemiology
  • Colorectal Cancer Treatments and Studies
  • Cancer Diagnosis and Treatment

Centro Universitário de Volta Redonda
2020-2025

ORCID
2024

Associação Fundo de Incentivo à Pesquisa
2023

UniBrasil Centro Universitário
2019

Hospital Araújo Jorge
2019

Instituto Nacional do Câncer
2019

Hospital Moinhos de Vento
2019

AC Camargo Hospital
2019

Hospital de Clínicas de Porto Alegre
2019

Hospital São Vicente
2019

Breast cancer (BC) in young women is uncommon and tends to present with more aggressive characteristics. To better understand characterize this scenario Brazil through real-world data, we performed a subanalysis of AMAZONA III study (ClinicalTrials.gov identifier: NCT02663973).The (GBECAM 0115) prospective registry that included 2,950 newly diagnosed invasive BC from January 2016 until March 2018 at 22 sites. Valid data were obtained 2,888 patients regarding age diagnosis complete baseline...

10.1200/jgo.19.00263 article EN cc-by-nc-nd Journal of Global Oncology 2019-11-15

Low rates of germline genetic testing (GGT) for breast cancer (BC) have been reported globally, with limited data from low- and middle-income countries (LMICs). In this study, we used real-world to assess the GGT rate BC in an LMIC identified barriers its use. We analyzed 2,974 newly diagnosed patients AMAZONA III largest Brazilian multicenter, prospective cohort. were determined entire cohort high-risk hereditary group (HR), defined by National Comprehensive Cancer Network criteria, between...

10.1200/go-24-00337 article EN cc-by-nc-nd JCO Global Oncology 2025-03-01

PURPOSE Adjuvant endocrine therapy (ET) improves the prognosis of patients with nonmetastatic estrogen receptor–positive (ER+) breast carcinoma; however, adherence is crucial to ensure its efficacy. In Brazil, data regarding ET are limited. We aimed evaluate across Brazil and characteristics associated adherence. METHODS Women ER+ invasive carcinoma who underwent for at least 6 months were enrolled. Adherence was assessed using Morisky Medication Scale-8 (MMAS-8) defined as an MMAS-8 score...

10.1200/go-24-00351 article EN cc-by-nc-nd JCO Global Oncology 2025-04-01

e23045 Background: Brazil’s participation in clinical research (CR) remains limited. Unawareness of CR benefits is a key barrier. Understanding patient perspectives crucial for addressing these challenges. We conducted national survey to explore cancer patients’ knowledge, fears, and misconceptions regarding CR, identifying factors that preclude their participation. Methods: This transversal observational study used self-administered questionnaire comprising validated sociodemographic...

10.1200/jco.2025.43.16_suppl.e23045 article EN Journal of Clinical Oncology 2025-05-28

Breast cancer is the most common malignancy in Brazilian women, with 66,280 new cases 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]). The trastuzumab biosimilar was first oncology approved Brazil for HER2-positive breast treatment. This study aimed to assess current level of knowledge biosimilars, comfort use, extrapolation indications, and switching practices among oncologists Brazil.A 24-question survey developed using an online platform that sought...

10.1200/go.20.00649 article EN cc-by-nc-nd JCO Global Oncology 2021-08-20

Abstract Background: Breast cancer (BC) is the most frequent in women Brazil, with more than 60,000 cases estimated annually. Forty percent of patients present stages III and IV neoadjuvant chemotherapy (NACT) remains mainstay treatment for locally advanced breast (LABC). Taxanes usually follow anthracyclines neo/adjuvant treatment, likely because their later introduction into clinical practice. However, potential impact alternative sequencing to be studied. A single-center phase II...

10.1158/1538-7445.sabcs22-ot2-22-02 article EN Cancer Research 2023-03-01

Abstract Background Currently, there are broadly differing patterns in the management of axilla after neoadjuvant chemotherapy (NAC) and no consensus with clinically strong evidence on subject. A survey was performed to assess current axillary NAC among Brazilian breast cancer surgeons. Methods The Society Mastology members were invited by email complete an anonymous online a total 426 responses collected. Results majority responders (67%) indicated performing routine staging physical exam,...

10.1002/jso.26104 article EN Journal of Surgical Oncology 2020-07-07

e12603 Background: Breast cancer (BC) is the most common invasive diagnosed in women worldwide. The risk of developing BC increases with age. Studies have shown that approximately up to half cases occur patients aged 65 years and older. To better understand characterize elderly Brazil, we performed a sub analysis AMAZONA III study (ClinicalTrials.gov identifier: NCT02663973). Methods: (GBCAM 0115) prospective cohort included 2,950 newly from January 2016 March 2018 23 Brazilian sites. For...

10.1200/jco.2021.39.15_suppl.e12603 article EN Journal of Clinical Oncology 2021-05-20

Purpose To reduce false-negative rates (FNR) in sentinel lymph node biopsy (SLNB) of clinically positive (cN+) axilla patients undergoing neoadjuvant chemotherapy (NAC). The removal three or more nodes with dual-tracer mapping including a radioisotope was used. However, the Brazilian Unified Health System, tracer is not feasible some hospitals. We conducted cross-sectional study to evaluate detection rate (SLN) who converted from cN+ ycN0 after NAC using blue dye as single-agent tracer....

10.1590/acb360608 article EN cc-by Acta Cirúrgica Brasileira 2021-01-01

Breast cancer is the most common female neoplasm in Brazil accounting for 73.610 new cases a year. The organization of public health system critical point to provide diagnosis and treatment these patients, considering that 75% population covered by (Sistema Único de Saúde, SUS). Waiting time procedures has been used evaluate accessibility can guide governmental strategies improve them. A retrospective study was conducted assessing medical records all patients registered at High Complexity...

10.18103/mra.v11i10.4577 article EN Medical Research Archives 2023-01-01

Background: Epidemiological and clinical cancer research is essential to understanding tumour behaviour developing new therapies in oncology.However, several countries including Brazil as well many other regions of the world have limited participation research.Despite 625,000 cases recorded 2022, only 2.2% ongoing trials are available country.We conducted an online survey describe physician engagement with identify main barriers precluding conduct country.Methods: An anonymous 23 objective...

10.3332/ecancer.2023.1640 article EN cc-by ecancermedicalscience 2023-11-23

Segundo dados do Instituto Nacional de Câncer (INCA), o câncer próstata é mais comum entre os homens no Brasil. Esse sofreu um aumento em sua incidência na perspectiva mundial devido ao envelhecimento populacional e sobrediagnóstico, por conta da disseminação rastreamento pelo Antígeno Prostático Específico (PSA). O objetivo trabalho analisar criticamente benefícios malefícios método rastreio através exame PSA. A metodologia utilizada apresenta análises dois ensaios clínicos larga escala que...

10.47385/tudoeciencia.949.2023 article PT Tudo é Ciência. 2023-12-20

Aproximadamente 10% dos casos de câncer mama e ovário são hereditários, sendo que mutações nos genes BRCA1/2 responsáveis por cerca 45% desses casos. O diagnóstico hereditário impacta no seguimento, tratamento prognóstico da paciente sua família. A realização do teste molecular para detecção das requer o preenchimento critérios estabelecidos pela diretriz Agência Nacional Saúde Suplementar (ANS) Brasil. Percebe-se, todavia, dificuldade reconhecimento encaminhamento pacientes risco os...

10.47385/interfaces..4451.2.2023 article PT Interfaces em Ciências da Saúde 2024-03-05

Clinical research is the cornerstone of improvements in cancer care. However, it has been conducted predominantly high-income countries with few clinical trials available Brazil and other low-and-middle-income (LMIC). Of note, less than one-third registered addressing some most commonly diagnosed cancers (breast, lung cervical) recruited patients from LMIC last years. The Institute Project CURA promoted fourth meeting, discussing barriers to proposing potential solutions. A meeting was held...

10.3332/ecancer.2024.1698 article EN cc-by ecancermedicalscience 2024-04-18

Abstract Background: Adjuvant ET reduces breast cancer recurrence and increases overall survival among patients with early-stage ER+ cancer, however a suboptimal number of in fact takes oral medicine as prescribed. In Brazil, there is paucity data about adherence to adjuvant ET. This study aims evaluate Brazilian women early clinical sociodemographic characteristics associated higher or lower adherence. Methods: Women history invasive carcinoma the on for at least 6 months were invited...

10.1158/1538-7445.sabcs23-po2-12-04 article EN Cancer Research 2024-05-02

Abstract Background Cancer registries in Brazil are deficient and data about patients’ profiles cancer treatment patterns scarce the country. Moreover, while 30% of population has access to private insurance, almost 70% uses publicly health services. The objective this work was describe sociodemographic clinicopathological characteristics women with early-stage ER+ breast on adjuvant ET different regions Brazil, for disease according public institutions. Methodology: We performed a...

10.1158/1538-7445.sabcs23-po1-09-12 article EN Cancer Research 2024-05-02

Abstract Introduction: Endocrine therapy (ET) plus CDK 4/6 inhibitors is considered the standard of care as first-line in hormone receptor positive (HR+)/HER2 negative (HER2-) metastatic breast cancer (mBC). Nonetheless, use chemotherapy (CT) frequent clinical practice, and access to limited some countries. We used real-world data describe treatment patterns, impact health insurance type, outcomes among Brazilian patients with HR+/HER2- mBC treated setting. Methods: In this observational...

10.1158/1538-7445.sabcs23-po3-05-03 article EN Cancer Research 2024-05-02

Abstract Background: Sexual dysfunction is a common health problem in women, and it can occur during breast cancer treatment survivorship. This study aims to determine the frequency of sexual disfunction among Brazilian women with early on adjuvant endocrine therapy explore its relationships patients’ clinical social characteristics, adherence ET, quality life, return work healthcare insurance. Methodology: Women history early-stage ER+ invasive carcinoma for at least 6 months were invited...

10.1158/1538-7445.sabcs23-po3-11-05 article EN Cancer Research 2024-05-02

Abstract Background: Breast cancer is the most common in women and its diagnosis treatment may adversely impact return to work (RTW). Previous showed that RTW varies from as low at 27% high 93%. There are few data about Latin America population. This study aims investigate Brazilian woman with early breast treated adjuvant endocrine therapy (ET) relations patients’ characteristics, duration of ET, healthcare insurance, quality life (QOL), sexual disfunction adherence. Methodology: Women a...

10.1158/1538-7445.sabcs23-po3-11-06 article EN Cancer Research 2024-05-02

Abstract Background: There is a significant scarcity of quality life (QOL) data among the Brazilian population with breast cancer. This study aims to evaluate QOL in women early cancer treated adjuvant endocrine therapy (ET) and explore its relationships patients’ clinical social characteristics, type duration healthcare insurance. Methodology: Women history early-stage estrogen-receptor positive invasive carcinoma on for at least 6 months were invited participate this study. assessment was...

10.1158/1538-7445.sabcs23-po5-11-10 article EN Cancer Research 2024-05-02
Coming Soon ...